 The method involves optical mapping of DNA sequences that are added as "barcodes" to antibodies attached to the cells in the sample.The method showed high reproducibility and achieved single-cell sensitivity.In addition to profiling cancer cells, the method shows promise as a clinical tool to identify pathway responses to molecularly targeted drugs and to predict drug response in patient samples.